CANbridge Pharmaceuticals Inc. (HKG:1228)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Development, Production, Marketing and Sale of Medical Products	49.98M	85.10M	102.87M	78.97M	31.16M
Development, Production, Marketing and Sale of Medical Products Growth	-41.27%	-17.27%	30.26%	153.43%	158.98%
Total	49.98M	85.10M	102.87M	78.97M	31.16M
Total Growth	-41.27%	-17.27%	30.26%	153.43%	158.98%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Chinese Mainland	49.92M	40.97M	55.87M	31.49M	7.35M
Chinese Mainland Growth	21.85%	-26.67%	77.43%	328.27%	34.97%
Other Countries/Regions	59.00K	44.13M	47.00M	47.48M	23.81M
Other Countries/Regions Growth	-99.87%	-6.10%	-1.02%	99.43%	261.60%
Total	49.98M	85.10M	102.87M	78.97M	31.16M
Total Growth	-41.27%	-17.27%	30.26%	153.43%	158.98%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 8, 2026

Data Sources Report a data error